These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16271939)

  • 1. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension.
    Nakamura K; Yamagishi S; Nakamura Y; Takenaka K; Matsui T; Jinnouchi Y; Imaizumi T
    Microvasc Res; 2005 Nov; 70(3):137-41. PubMed ID: 16271939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T; Yamagishi S; Ueda S; Nakamura K; Imaizumi T; Takeuchi M; Inoue H
    J Int Med Res; 2007; 35(4):482-9. PubMed ID: 17697525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation.
    Yamagishi S; Matsui T; Nakamura K; Takeuchi M; Inoue H
    Protein Pept Lett; 2008; 15(8):850-3. PubMed ID: 18855759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression.
    Yamagishi S; Takeuchi M; Matsui T; Nakamura K; Imaizumi T; Inoue H
    FEBS Lett; 2005 Aug; 579(20):4265-70. PubMed ID: 16051229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.
    Forbes JM; Thorpe SR; Thallas-Bonke V; Pete J; Thomas MC; Deemer ER; Bassal S; El-Osta A; Long DM; Panagiotopoulos S; Jerums G; Osicka TM; Cooper ME
    J Am Soc Nephrol; 2005 Aug; 16(8):2363-72. PubMed ID: 15930093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
    Yamagishi S; Matsui T; Nakamura K; Inoue H; Takeuchi M; Ueda S; Fukami K; Okuda S; Imaizumi T
    Microvasc Res; 2008 Jan; 75(1):130-4. PubMed ID: 17560613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors.
    Rüster C; Bondeva T; Franke S; Tanaka N; Yamamoto H; Wolf G
    Am J Nephrol; 2009; 29(6):538-50. PubMed ID: 19129693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats.
    Hasegawa G; Fukui M; Hosoda H; Asano M; Harusato I; Tanaka M; Shiraishi E; Senmaru T; Sakabe K; Yamasaki M; Kitawaki J; Fujinami A; Ohta M; Obayashi H; Nakamura N
    Eur J Pharmacol; 2009 Mar; 605(1-3):164-9. PubMed ID: 19171132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Pharmacol Res; 2010 Jan; 61(1):34-9. PubMed ID: 19635564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
    Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
    Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells.
    Fujita M; Okuda H; Tsukamoto O; Asano Y; Hirata YL; Kim J; Miyatsuka T; Takashima S; Minamino T; Tomoike H; Kitakaze M
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):e138-42. PubMed ID: 16888237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells.
    Matsui T; Nishino Y; Maeda S; Takeuchi M; Yamagishi S
    Microvasc Res; 2011 May; 81(3):269-73. PubMed ID: 21236267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation.
    Yamagishi S; Takeuchi M
    Drugs Exp Clin Res; 2004; 30(4):169-75. PubMed ID: 15553663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
    Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
    Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan inhibits AGE-induced podocyte damage and detachment.
    Fukami K; Yamagishi S; Kaifu K; Matsui T; Kaida Y; Ueda S; Takeuchi M; Asanuma K; Okuda S
    Microvasc Res; 2013 Jul; 88():79-83. PubMed ID: 23648312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
    Ihara Y; Egashira K; Nakano K; Ohtani K; Kubo M; Koga J; Iwai M; Horiuchi M; Gang Z; Yamagishi S; Sunagawa K
    J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
    Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker.
    Shao J; Nangaku M; Inagi R; Kato H; Miyata T; Matsusaka T; Noiri E; Fujita T
    J Hypertens; 2007 Aug; 25(8):1643-9. PubMed ID: 17620961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease.
    Mahajan N; Malik N; Bahl A; Dhawan V
    Atherosclerosis; 2009 Dec; 207(2):597-602. PubMed ID: 19576587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.